卵巢上皮性癌是常见的妇科恶性肿瘤,早期诊断非常困难,70%以上的患者就诊时已属晚期,5年生存率滞留在30%左右。早发现、早诊断、早治疗对卵巢癌的预后至关重要。卵巢癌的早期诊断、疗效评估多依靠肿瘤标志物,但敏感性和特异性均不够理想。故寻求理想的标记物早期诊断、评估化疗的敏感性,对提高临床疗效具有重要意义。ctDNA是肿瘤细胞脱落或凋亡后释放进入循环系统的DNA片段。有文献证明在肿瘤患者中ctDNA可以被定性、定量和追踪,可以用于肿瘤的早期发现和治疗评估。 Epithelial ovarian cancer is a common gynecological malignancy, early diagnosis is very difficult, more than 70% of patients have been treated at advanced stage, 5-year survival rate remained at about 30%. Early detection, early diagnosis, early treatment of ovarian cancer prognosis is crucial. Early diagnosis of ovarian cancer, efficacy evaluation depends on tumor markers, but the sensitivity and specificity are not ideal. Therefore, the search for ideal markers for early diagnosis, to assess the sensitivity of chemotherapy, to improve the clinical efficacy of great significance. ctDNA is a DNA fragment that is released into the circulatory system after the tumor cells have shed or become apoptotic. There is literature that ctDNA can be characterized, quantified and tracked in cancer patients and can be used for early detection and treatment of tumors.